Results for tag: "Lutathera"

Lutathera is an oncology drug used to treat certain types of neuroendocrine tumors. It is a peptide receptor radionuclide therapy (PRRT) that combines the targeting of a peptide receptor with the therapeutic effect of a radionuclide. The drug is administered intravenously and works by delivering radiation directly to the tumor cells, while sparing healthy tissue. The Lutathera market is a rapidly growing segment of the oncology drug market. It is expected to experience strong growth in the coming years due to its effectiveness in treating neuroendocrine tumors. The drug is also being studied for its potential to treat other types of cancer, such as prostate and breast cancer. The Lutathera market is highly competitive, with several major players. These include Novartis, Advanced Accelerator Applications, and Endocyte. Other companies in the market include Ipsen, Merck, and Pfizer. Show Less Read more